Clinical Trial

Radiation Combined With BCMA/CD3 Bispecific Antibody Therapy for Solitary Bone Plasmacytoma With Mild Bone Marrow Infiltration

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, single-center clinical trial designed to evaluate the safety and efficacy of radiation combined with a BCMA/CD3 bispecific antibody (CM336) in patients with solitary bone plasmacytoma (SBP) with mild bone marrow infiltration.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT07115667
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Solitary Bone Plasmacytoma, Plasmacytoma of Bone, Plasma Cell Disorders
Enrollment 21 participants
Start Date 2025-08-25
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-08